PT2978419T - Composições para melhorar a viabilidade celular e métodos da sua utilização - Google Patents

Composições para melhorar a viabilidade celular e métodos da sua utilização

Info

Publication number
PT2978419T
PT2978419T PT147756753T PT14775675T PT2978419T PT 2978419 T PT2978419 T PT 2978419T PT 147756753 T PT147756753 T PT 147756753T PT 14775675 T PT14775675 T PT 14775675T PT 2978419 T PT2978419 T PT 2978419T
Authority
PT
Portugal
Prior art keywords
compositions
methods
cell viability
improving cell
improving
Prior art date
Application number
PT147756753T
Other languages
English (en)
Original Assignee
Amylyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51569584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2978419(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylyx Pharmaceuticals Inc filed Critical Amylyx Pharmaceuticals Inc
Publication of PT2978419T publication Critical patent/PT2978419T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT147756753T 2013-03-24 2014-02-24 Composições para melhorar a viabilidade celular e métodos da sua utilização PT2978419T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361804690P 2013-03-24 2013-03-24
US14/140,083 US9872865B2 (en) 2013-03-24 2013-12-24 Compositions for improving cell viability and methods of use thereof

Publications (1)

Publication Number Publication Date
PT2978419T true PT2978419T (pt) 2020-06-19

Family

ID=51569584

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147756753T PT2978419T (pt) 2013-03-24 2014-02-24 Composições para melhorar a viabilidade celular e métodos da sua utilização

Country Status (20)

Country Link
US (7) US9872865B2 (pt)
EP (2) EP2978419B1 (pt)
JP (5) JP6495237B2 (pt)
KR (6) KR20210025134A (pt)
CN (3) CN105050593B (pt)
AU (4) AU2014242123B2 (pt)
CA (1) CA2908683A1 (pt)
CY (1) CY1123092T1 (pt)
DK (1) DK2978419T3 (pt)
ES (1) ES2796250T3 (pt)
HK (1) HK1216851A1 (pt)
HR (1) HRP20200990T1 (pt)
HU (1) HUE051105T2 (pt)
LT (1) LT2978419T (pt)
ME (1) ME03747B (pt)
PL (1) PL2978419T3 (pt)
PT (1) PT2978419T (pt)
RS (1) RS60596B1 (pt)
SI (1) SI2978419T1 (pt)
WO (1) WO2014158547A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
EP3307262B1 (en) * 2015-06-15 2021-05-19 NMD Pharma A/S Compounds for use in treating neuromuscular disorders
KR101743960B1 (ko) * 2015-07-06 2017-06-08 서울대학교산학협력단 G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물
EP3347486A4 (en) * 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
JP2019526612A (ja) 2016-09-12 2019-09-19 スティーブン・ホフマン 認知症を治療するための組成物
US20210293794A1 (en) * 2017-02-24 2021-09-23 University Of Hawii Cancer Center Metabolic biomarkers for the identification and characterization of alzheimers disease
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
CA3123378A1 (en) * 2018-12-18 2020-06-25 Santen Pharmaceutical Co., Ltd. Agent containing 4-phenylbutyrate, for preventing or treating presbyopia
KR20220098682A (ko) 2019-05-14 2022-07-12 타임, 인크. 암을 치료하기 위한 조성물 및 방법
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
JP2023507153A (ja) 2019-12-16 2023-02-21 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 筋萎縮性側索硬化症及び関連する疾患の治療
JP2023518670A (ja) * 2020-02-13 2023-05-08 プリレニア ニューロセラピューティクス リミテッド プリドピジンおよび他の活性薬剤を使用して筋萎縮性側索を治療するための併用療法
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2022188029A1 (zh) * 2021-03-09 2022-09-15 兆科药业（广州）有限公司 一种含牛磺熊去氧胆酸、苯丁酸钠的复方散剂/颗粒剂、制备方法、用途以及其药物组合物
WO2022191296A1 (ja) * 2021-03-10 2022-09-15 昭和電工マテリアルズ株式会社 培地組成物、細胞培養物の製造方法、及び細胞懸濁物
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
CN113349300A (zh) * 2021-06-07 2021-09-07 湖南农业大学 4-苯基丁酸在制备猪肠道保健产品中的应用
CA3237768A1 (en) * 2021-11-08 2023-05-11 Amylyx Pharmaceuticals, Inc. Combination of turso and sodium phenyl butyrate for the treatment of neurodegenerative diseases
WO2023102149A1 (en) * 2021-12-02 2023-06-08 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
US20230277630A1 (en) 2022-03-02 2023-09-07 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
US20230364110A1 (en) 2022-05-12 2023-11-16 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
US20230372263A1 (en) 2022-05-17 2023-11-23 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
WO2024015286A1 (en) * 2022-07-11 2024-01-18 AI Therapeutics, Inc. Apilimod combination therapy
WO2024015281A1 (en) * 2022-07-11 2024-01-18 AI Therapeutics, Inc. Apilimod combination therapy
US20240100069A1 (en) 2022-09-07 2024-03-28 Amylyx Pharmaceuticals, Inc. Methods and Compositions for Treating Amyotrophic Lateral Sclerosis
US20240139211A1 (en) 2022-09-29 2024-05-02 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
WO2024095118A1 (en) 2022-10-31 2024-05-10 Novartis Ag Dosing regimen of a csf-1r inhibitor for use in the treatment of amyotrophic lateral sclerosis
WO2024105168A1 (en) 2022-11-18 2024-05-23 Inflectis Bioscience Novel combinations useful for the treatments of als

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
AU2003230767A1 (en) 2003-04-02 2004-11-23 Regents Of The University Of Minnesota Methods of promoting cell viability
ES2358089T3 (es) 2004-11-01 2011-05-05 Seo Hong Yoo Métodos y composiciones para reducir la neurodegeneración en esclerosis lateral amiotrófica.
CA2585471A1 (en) 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
EP1871385A1 (en) 2005-02-10 2008-01-02 Regents Of The University Of Minnesota Methods for treating visual disorders
EP2001484A4 (en) 2006-03-22 2010-04-21 Harvard College METHOD AND COMPOSITIONS FOR TREATING HYPERCHOLESTERINEMIA AND ATHEROSCLEROSIS
US7737175B2 (en) 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
US20090252704A1 (en) * 2008-01-14 2009-10-08 Green Allan M Therapies for cognition and learning enhancement
ES2332687B1 (es) 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
US9283277B2 (en) 2008-05-12 2016-03-15 Children's Medical Center Corporation Methods and compositions for the treatment of obesity
WO2010008860A1 (en) 2008-06-23 2010-01-21 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
EP2391370B1 (en) 2009-02-02 2015-06-03 Galmed Research and Development Ltd. Methods and compositions for treating alzheimer's disease
EP2422787A1 (en) 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
WO2013067096A2 (en) 2011-11-01 2013-05-10 Metselex, Inc. Prevention or attenuation of neuropathic pain and kidney injury by tauroursodeoxycholic acid
EP2599477A1 (en) 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
WO2013142490A2 (en) 2012-03-20 2013-09-26 Metselex, Inc. Tauroursodeoxycholic acid attenuates or abolishes formation and deposition of amyloid-b peptide
US9872865B2 (en) * 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
PT3016654T (pt) 2013-07-01 2018-11-09 Bruschettini Srl Ácido tauroursodeoxicólico (tudca) para utilização no tratamento de doenças neurodegenerativas
US10142799B2 (en) 2014-08-19 2018-11-27 Qualcomm Incorporated Multicasting traffic using multi-connectivity

Also Published As

Publication number Publication date
KR20220148337A (ko) 2022-11-04
JP7080944B2 (ja) 2022-06-06
KR20150135471A (ko) 2015-12-02
US10857162B2 (en) 2020-12-08
JP6766198B2 (ja) 2020-10-07
US20220110948A1 (en) 2022-04-14
AU2014242123B2 (en) 2018-11-01
AU2014242123A1 (en) 2015-09-17
US10251896B2 (en) 2019-04-09
HK1216851A1 (zh) 2016-12-09
SI2978419T1 (sl) 2020-11-30
WO2014158547A1 (en) 2014-10-02
US11071742B2 (en) 2021-07-27
EP2978419A1 (en) 2016-02-03
AU2019200658A1 (en) 2019-02-21
JP2019123721A (ja) 2019-07-25
HRP20200990T1 (hr) 2020-10-16
US20220160733A1 (en) 2022-05-26
ES2796250T3 (es) 2020-11-26
CN105050593B (zh) 2019-12-03
KR102460746B1 (ko) 2022-10-31
RS60596B1 (sr) 2020-08-31
CN109999043B (zh) 2023-01-20
KR20210025134A (ko) 2021-03-08
PL2978419T3 (pl) 2020-10-19
KR102396714B1 (ko) 2022-05-12
EP2978419A4 (en) 2016-11-16
LT2978419T (lt) 2020-08-10
KR102223250B1 (ko) 2021-03-08
EP3750531A1 (en) 2020-12-16
EP2978419B1 (en) 2020-04-15
US9872865B2 (en) 2018-01-23
JP7242945B2 (ja) 2023-03-20
ME03747B (me) 2021-04-20
KR20210156312A (ko) 2021-12-24
JP2016515575A (ja) 2016-05-30
JP2021008473A (ja) 2021-01-28
CN105050593A (zh) 2015-11-11
AU2019200658B2 (en) 2020-12-24
KR20220066178A (ko) 2022-05-23
JP2022122929A (ja) 2022-08-23
DK2978419T3 (da) 2020-05-04
CN109999043A (zh) 2019-07-12
KR102607635B1 (ko) 2023-11-30
US20200230156A1 (en) 2020-07-23
US20190255072A1 (en) 2019-08-22
KR20230164242A (ko) 2023-12-01
AU2021201770A1 (en) 2021-04-15
CN110787169B (zh) 2023-10-20
AU2021201770B2 (en) 2022-05-26
JP2023085274A (ja) 2023-06-20
HUE051105T2 (hu) 2021-03-01
US20140288030A1 (en) 2014-09-25
JP6495237B2 (ja) 2019-04-03
CA2908683A1 (en) 2014-10-02
CN110787169A (zh) 2020-02-14
AU2022221410A1 (en) 2022-09-15
US20200171052A1 (en) 2020-06-04
CY1123092T1 (el) 2021-10-29
US20180098999A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
HK1216851A1 (zh) 用於提高細胞存活力的組合物和使用該組合物的方法
HK1219975A1 (zh) 用於病毒生產的細胞系和使用方法
HK1221978A1 (zh) 組合物及其使用方法
HK1210494A1 (zh) 用於細胞培養的裝置和方法
EP2834322A4 (en) BIOCHARBON COMPOSITIONS AND METHODS OF USE
IL244296A0 (en) Cell-permeable conjugates and methods of using them
EP2968549A4 (en) CELL CULTURE METHODS
EP2836224A4 (en) COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
EP2971014A4 (en) CELL CULTURE METHODS
EP2971040A4 (en) CELL CULTURE METHODS
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
GB201200458D0 (en) Methods of preparing cells and compositions
EP2968244A4 (en) COMPOSITIONS AND METHODS FOR USING ALIGAL COMPOUNDS
IL239631B (en) Anti-integrin cell 1 antibody preparations and methods of using them
IL245272B (en) pif-transfected cells and methods of use
EP2906041A4 (en) COMPOSITIONS AND METHODS OF USING INAPPETENCE COMPOUND
IL233961B (en) The composition of a phytogenic supplement and methods of its use
HK1210436A1 (en) Novel cell compositions and methods
EP2971002A4 (en) CELL CELL EXPRESSION CASSETTE COMPOSITIONS AND METHODS OF USE
HK1219292A1 (zh) +細胞組合物及其使用方法
GB201307377D0 (en) Devices and methods for culture of cells
EP2841164A4 (en) COMPOSITIONS AND USE PROCEDURES FOR THE SKIN
GB201310349D0 (en) Composition and method of use thereof
GB201301928D0 (en) Composition and method of use thereof